CONTINEUM THERAPEUTICS INC-A
CTNMNASDAQTrading Snapshot
- Day Range
- $13.35 – $13.56
- 52-Week Range
- $8.60 – $17.79
- Volume
- $3.67B
- Avg Volume
- $4.32B
- Shares Outstanding
- 37.6M
- Next Earnings
- Nov 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $136M
- Last Q Revenue
- $33M
- P/E Ratio
- -7.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.54
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.4%
Why Investors Own CTNM
- ✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CONTINEUM THERAPEUTICS INC-A
CTNM
StockOtter · stockotter.spaceAbout CONTINEUM THERAPEUTICS INC-A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC lessened its position in shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM) by 80.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchan
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst Downgrade
Shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) dropped 9.9% during mid-day trading on Tuesday after JonesTrading lowered their price target on the stock from $26.00 to $24.00. JonesTrading curren
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint.
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibro
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibro
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibro